Edition:
United Kingdom

Novozymes A/S (NZYMb.CO)

NZYMb.CO on Copenhagen Stock Exchange

326.80DKK
10:06am BST
Change (% chg)

kr.1.90 (+0.58%)
Prev Close
kr.324.90
Open
kr.325.90
Day's High
kr.328.30
Day's Low
kr.325.10
Volume
65,024
Avg. Vol
663,034
52-wk High
kr.360.70
52-wk Low
kr.268.00

Summary

Name Age Since Current Position

Joergen Buhl Rasmussen

63 2017 Independent Chairman of the Board

Peder Holk Nielsen

61 2013 President, Chief Executive Officer

Agnete Raaschou-Nielsen

61 2017 Independent Vice Chairman of the Board

Prisca Havranek-Kosicek

43 2018 Chief Financial Officer & Executive Vice President, Corporate Functions

Thomas Videbaek

57 2016 Chief Operating Officer; Executive Vice President, Research, Innovation & Supply

Andrew Fordyce

55 2016 Executive Vice President, Food & Beverages

Anders Lund

45 2016 Executive Vice President, Household Care & Technical

Tina Sejersgaard Fanoe

49 2016 Executive Vice President, Agriculture & Bioenergy

Lena Bech Halskov

51 2013 Director, Employee Representative

Lars Green

50 2014 Director

Anders Hentze Knudsen

59 2013 Director, Employee Representative

Lars Koeppler

56 2010 Director, Employee Representative

Kasim Kutay

52 2017 Director

Patricia Malarkey

52 2018 Director

Kim Stratton

56 2017 Independent Director

Mathias Uhlen

64 2007 Independent Director

Tobias Bjorklund

2017 Head of Investor Relations

Biographies

Name Description

Joergen Buhl Rasmussen

Mr. Joergen Buhl Rasmussen has been Independent Chairman of the Board of Directors of Novozymes A/S since February 22, 2017. He has previously been Independent Vice Chairman of the Board since February 24, 2016. He has been Independent Member of the Board of Directors at the Company from March 1, 2011 until February 24, 2016. He serves as Member of the Audit Committee and Chairman of Nomination and Remuneration Committee. He is also Member of the Board of Directors at Smurfit Kappa Group and Human Practice Foundation as well as Member of Advisory Board of Axcel. He is also Chairman of F. Uhrenholt A/S. He has competencies in acquisitions, international business and management, specifically within sales, marketing, and branding. He is also Adjunct Professor at Copenhagen Business School.

Peder Holk Nielsen

Mr. Peder Holk Nielsen has been President and Chief Executive Officer (CEO) of Novozymes A/S since April 1, 2013. Previously, he served as Executive Vice President of Enzyme Business at the Company from 2007 and as Executive Vice President of Business Operations from 2000. He is also Member of the Board of Directors at Hempel A/S and LEO Pharma A/S. He joined Novo A/S in 1984 as Product Manager of Enzymes Division. In 1987, he became Head of the New Business Development Group. He took over as Vice President in Research & Development in the Enzyme Process Division in 1990. In 1995, he joined the management team of the enzyme business in Novo Nordisk A/S initially as head of Development and Quality Management, and from 1999 he led Sales and Marketing in the enzymes business. He held this position until the demerger of Novozymes from Novo Nordisk. With the creation of Novozymes in 2000, he continued running the operational side of the business as Executive Vice President, responsible for Sales, Marketing and Supply Chain activities. In 2007, he assumed responsibility for all of Enzyme Business, including production, procurement, development and quality management. He holds Master of Science degree in Chemical Engineering from the Technical University of Denmark (Danmarks Tekniske Universitet) from 1981, and Doctorate of Philosophy degree from the Institute of Chemical Engineering at the Technical University of Denmark from 1984. He also holds Bachelor of Commerce degree in International Business Management from the Copenhagen Business School from 1985.

Agnete Raaschou-Nielsen

Ms. Agnete Raaschou-Nielsen has been Independent Vice Chairman of the Board of Directors of Novozymes A/S since February 22, 2017. She has previously been Independent Director since February 24, 2016. Previously, she was Independent Vice Chairman of the Board of Directors at the Company from February 26, 2014 until February 24, 2016. She has been Independent Member of the Board of Directors of the Company since March 1, 2011. She is also Member of the Company's Audit Committee and Nomination and Remuneration Committee. She is also Chairman of the Board of Directors at Brdr. Hartmann A/S, Arkil Holding A/S, and Chairman of the Board of Directors at Danske Invest, three other UCITS funds and two AIF funds. She acts as Member of the Boards of Directors at Danske Invest Management A/S and Aktieselskabet Schouw & Co. She is also Member of the Audit Committee of Aktieselskabet Schouw & Co. She has competencies in business development and acquisitions, macroeconomics and intellectual property rights.

Prisca Havranek-Kosicek

Ms. Prisca Havranek-Kosicek has been appointed Chief Financial Officer and Executive Vice President, Corporate Functions at NOVOZYMES A/S, effective as of February 1, 2018. Until November 2017, she was Member of the Management and Chief Financial Officer at Kuoni group. Before that, she held various positions at Royal DSM from 2011 till 2016, including as Group Treasurer and CFO for DSM's pharma division. Between 2004 and 2008, she was Vice President, Corporate Subsidiaries and Investor Relations at Austrian Airlines Group. She holds Ph.D. in Business Administration from University of Economics and Business in Vienna. She is Member of the Board of Allianz Elementar Versicherungs-AG and Allianz Elementar Lebensversicherungs-AG.

Thomas Videbaek

Dr. Thomas Videbaek has been Chief Operating Officer and Executive Vice President, Research, Innovation & Supply at Novozymes A/S since February 8, 2016. Previously, he was Executive Vice President of Business Development at the Company from April 1, 2013 until February 8, 2016. Before that, he served as Executive Vice President of BioBusiness at the Company since September 2007. He is also Member of the Board of Directors of Evolva SA. He joined Novo Nordisk as Chemist in 1988 in Technical Service, Textile Enzymes. From 1990 to 1991, he served as Business Development Manager for Textile in the United States, and was later appointed Global Marketing Manager for Textile. In 1995, he became Global Marketing Director for Starch, and in 1996, he also assumed responsibility for Food and Feed enzymes, and was appointed Director for Strategic Marketing, Food and Feed enzymes, where he became responsible for analyzing market possibilities and developing marketing strategies and plans for the food and feed industries. In 1998, he was appointed General Manager for Novozymes Switzerland, as well as Vice President for Cereal Food and Beverage Marketing. In 2003, he became Vice President for Supply Chain Operations with responsibility for establishing a global organization in charge of the supply chain at Novozymes. In 2005, he became Vice President for Sales and Customer Solutions with responsibility for the global Sales and Customer Solutions organization. He holds a Master of Science degree in Chemical Engineering degree from the Technical University of Denmark's (Danmarks Tekniske Universitet) Department of Nutrition and Biochemistry in Copenhagen from 1986, and a Doctorate of Philosophy degree from the Technical University of Denmark from 1990. He also holds a Bachelor of Commerce degree in International Business from the Copenhagen Business School from 1992.

Andrew Fordyce

Mr. Andrew Fordyce has been Executive Vice President, Food & Beverages at Novozymes A/S since February 8, 2016. Previously, he was Executive Vice President of Business Operations at the Company from April 1, 2013 until February 8, 2016. He was previously Vice President of Sales and Customer Solutions. Since joining the Company in 1993, he has held several positions in commercial operations, research and development and production in Denmark, Switzerland and the United States. He holds Doctorate of Philosophy degree in Chemical Engineering from the University of Texas at Austin.

Anders Lund

Mr. Anders Lund has been Executive Vice President, Household Care & Technical at Novozymes A/S since February 8, 2016. Formerly, he was Vice President of Sales at the Company. He holds Master of Science in Economics from Aarhus University, Denmark. He started his career with the company in 1999 and has held various leadership positions across Marketing, Sales and as Head of Supply Chain.

Tina Sejersgaard Fanoe

Ms. Tina Sejersgaard Fanoe has been Executive Vice President, Agriculture & Bioenergy at Novozymes A/S since February 8, 2016. She is also Board Member of DLF A/S. Previously, she was Vice President of Sales at the Company. She holds a Master of Science in Chemical Engineering from the Technical University of Denmark, as well as a Bachelor of Arts degree in philosophy and education from Copenhagen University, Denmark. She started her career with the company in 1993 and has held various positions within R&D, Marketing, Business Development and Sales.

Lena Bech Halskov

Ms. Lena Bech Halskov has been Employee Representative on the Board of Directors of Novozymes A/S since February 28, 2013. She works as Safety Adviser.

Lars Green

Mr. Lars Hall Green has been Member of the Board of Directors of Novozymes A/S since February 26, 2014. He is Chairman of the Company's Audit Committee. He is also Executive Vice President, Business Services and Compliance at Novo Nordisk A/S. He has international experience from managing global biotech and biopharma companies, and financial and accounting expertise.

Anders Hentze Knudsen

Mr. Anders Hentze Knudsen has been Employee Representative on the Board of Directors at Novozymes A/S since February 28, 2013. He works as Senior Operator.

Lars Koeppler

Mr. Lars Bo Koeppler has served as Employee Representative on the Board of Directors at Novozymes A/S since December 1, 2010. He is Technician. Previously, he was Member of the Company's Board of Directors until 2004.

Kasim Kutay

Mr. Kasim Kutay has been Director of NOVOZYMES A/S since February 22, 2017. He is CEO of Novo Holdings A/S. He also serves as Board Member of Novo Nordisk A/S and ConvaTec Plc. He has experience within biotechnology, mergers and acquisitions, and financial and accounting expertise.

Patricia Malarkey

Kim Stratton

Ms. Kim Stratton has been Independent Director at NOVOZYMES A/S since February 22, 2017. She is Member of the Nomination and Remuneration Committee. She is Head of International Commercial, Shire International GmbH. She also serves as Board Member of European Federation of Pharmaceutical Industries and Associations (EFPIA). She has international commercial experience within sales and marketing, emerging markets, innovation pipeline management and sustainability.

Mathias Uhlen

Mr. Mathias Uhlen has been Independent Member of the Board of Directors at Novozymes A/S since 2007. He is Professor at the Royal Institute of Technology (Kungliga Tekniska Hogskolan - KTH) in Stockholm, Sweden and the Technical University of Denmark (Danmarks Tekniske Universitet, DTU). He is also Chairman of the Board of Directors at Antibodypedia AB, ScandiBio Therapeutics AB and Atlas Antibodies AB, as well as Vice Chairman of the Board of Directors at Affibody Medical AB. He also acts as Member of the Board of Bure Equity AB. He has experience in research and biotechnology.

Tobias Bjorklund